Gruppo Italiano Malattie Ematologiche Dell'adulto
Clinical trials sponsored by Gruppo Italiano Malattie Ematologiche Dell'adulto, explained in plain language.
-
Real-World look at myelofibrosis Drug's impact on spleen size
Disease control Not yet recruitingThis study aims to observe how well the drug momelotinib works for people with myelofibrosis in everyday medical practice. It will follow 93 adults with the condition who are already taking the drug as part of their standard care. The main goal is to see if the treatment reduces …
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New test could spot hidden leukemia mutations sooner
Diagnosis Not yet recruitingThis study aims to see if a new, highly sensitive blood test (called digital PCR) is as good as the current standard test (NGS) at finding specific mutations that make chronic myeloid leukemia (CML) resistant to certain drugs. It will involve 150 adult CML patients whose current …
Phase: NA • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Diagnosis
Last updated Mar 23, 2026 15:16 UTC
-
Doctors review past cases to gauge leukemia Drug's Real-World impact
Knowledge-focused Not yet recruitingThis study looks back at the medical records of about 100 adults with a specific type of leukemia (Philadelphia-positive ALL) who were already treated with the drug ponatinib as part of their regular care. The goal is to see how effective the treatment was in a real-world setting…
Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Apr 02, 2026 14:56 UTC